Commentary

Interaction Between Adalimumab With Concurrent Pregabalin and Duloxetine Administration in a Psoriasis Patient With Diabetic Peripheral Neuropathy [letter]

Cutis. 2011 May;87(5):249,250
By
Wu JJ
Fleming KF

Wu JJ, Fleming KF

No abstract available.
PDF Download

 

Recommended Reading

Belimumab's FDA Approval Marks New Lupus-Treatment Era
Psoriasis Collection
Sildenafil Reduces Attack Frequency in Raynaud's
Psoriasis Collection
SDEF: Consider Potential Risks of Newly Approved Therapeutics
Psoriasis Collection
SDEF: Psoriasis Comorbidities Carry Implications for Disease Management
Psoriasis Collection
Biologics Tied to Greater Risk of Adverse Events
Psoriasis Collection
Psoriasis Linked With 6% Higher Cardiovascular Disease Risk
Psoriasis Collection
Heart Involvement in Systemic Sclerosis Underappreciated
Psoriasis Collection
Study: Scleroderma Survival Improving
Psoriasis Collection
Cancer Risk Greater in Treated RA Patients Than in General Population
Psoriasis Collection
Ask the Expert: Scleroderma Mimics
Psoriasis Collection